Nervgen Pharma Corp (TSE:NGEN) has released an update.
NervGen Pharma Corp., a clinical-stage biotech company, announced that Bill Radvak is stepping down from his role on the Board of Directors and will now serve as an advisor. The company is preparing for its Annual General Meeting on June 4, 2024, and is in the process of identifying a new board candidate. NervGen, known for developing treatments for nervous system repair, expressed gratitude to Radvak for his significant contributions since co-founding the company.
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.